Who Owns Cullinan Therapeutics Stock?
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 110.53%
- Institutions (% of float)
- 111.18%
- Held by insiders
- 0.58%
- Institutional holders
- 261
- Institutions 99.4%
- Insiders 0.6%
- Public and other 0.0%
Who owns Cullinan Therapeutics stock?
Institutional investors own about 110.5% of Cullinan Therapeutics's shares, spread across 261 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.58% of CGEM.
The largest institutional holders are MPM Bioimpact LLC (14.99%), Lynx1 Capital Management Lp (13.81%) and BVF Inc. (8.86%). Together, the top 10 institutions control 70.9% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their CGEM positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CGEM
| Institution | Shares | % Held | Change |
|---|---|---|---|
| MPM Bioimpact LLC | 9.73M | 14.99% | +27.2% |
| Lynx1 Capital Management Lp | 8.96M | 13.81% | 0.0% |
| BVF Inc. | 5.75M | 8.86% | 0.0% |
| Blackrock Inc. | 5.23M | 8.06% | +17.6% |
| Price (T.Rowe) Associates Inc | 3.83M | 5.89% | +88.5% |
| Kynam Capital Management, LP | 3.11M | 4.80% | 0.0% |
| Vanguard Capital Management LLC | 2.61M | 4.03% | +5.3% |
| State Street Corporation | 2.60M | 4.01% | -29.0% |
| RTW Investments LP | 2.36M | 3.64% | +38.6% |
| Siren, L.L.C. | 1.79M | 2.76% | -5.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CGEM
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.93M | 2.97% |
| iShares Trust-iShares Russell 2000 ETF | 1.57M | 2.42% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.23M | 1.89% |
| T. Rowe Price New Horizons Fund, Inc. | 1.02M | 1.57% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 662.88K | 1.02% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 621.22K | 0.96% |
| T. Rowe Price Health Sciences Fund, Inc. | 583.80K | 0.90% |
| iShares Trust-iShares Russell 2000 Value ETF | 573.55K | 0.88% |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 559.80K | 0.86% |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 452.66K | 0.70% |
Frequently asked questions
Who is the largest shareholder of Cullinan Therapeutics?
MPM Bioimpact LLC is the largest institutional shareholder of CGEM, owning 14.99% of shares outstanding (9.73M shares) as of its latest 13F filing.
What percentage of Cullinan Therapeutics is owned by institutions?
Institutions own about 110.5% of CGEM shares and 111.2% of the public float.
How much of Cullinan Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.58% of CGEM shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.